BioSpace News Archive

Focusing on transformation into a commercial stage biopharmaceutical company and the potential of its unique antibody-cleaving enzyme platform beyond transplantation in areas such as autoimmunity and gene therapy

Data is part of Genentech’s MORPHEUS umbrella program and covers patients with resistant/refractory NSCLC treated with ciforadenant in combination with atezolizumab

Step-down responses to GEN-009, with 3 objective responses (2 PR, 1 CR) in the first 5 patients, suggests added benefit to PD-1 inhibitor therapy

Agendia, Inc., a world leader in precision oncology for breast cancer, presented data at the European Society for Medical Oncology Virtual Congress 2020 showing that MammaPrint’s Ultra-Low risk threshold can identify postmenopausal breast cancer patients who will have an excellent prognosis with limited or no tamoxifen treatment.

Triplet Combination Demonstrates Encouraging Anti-Tumor Activity and Tolerability in Recurrent Platinum-Sensitive Ovarian Cancer

Initial data from the Phase 1b part of the LIO-1 trial of lucitanib combined with Opdivo® (nivolumab) in advanced metastatic solid tumors identify a recommended Phase 2 dose and show promising signs of antitumor activity

78% overall response rate (ORR) and median progression-free survival (PFS) of 36.8 months demonstrate durable response in expanded data set of 175 adults and children

Biofidelity Ltd, the cancer diagnostics company, announces the appointment of Stephen Miller as Chief Commercial Officer, based in the US. Following Biofidelity’s recent $12m Series A financing, supported by experienced investors BlueYard Capital, Longwall Ventures and Agilent Technologies, the Company is now focused on expanding its executive team, a critical step in its commercial strategy.

CEBINA GmbH, an Austrian biotech company, announces further positive results in its collaborative COVID-19 drug repurposing project, demonstrating that a common allergy nasal spray medication containing azelastine has potent efficacy against SARS-CoV-2 in a human 3D nasal tissue model.

MYR Pharmaceuticals, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis B and D, is pleased to announce that HEPCLUDEX® has successfully launched in Germany, France and Austria.